Arrhythmogene Effekte von Antiarrhythmika: Bedeutung elektrophysiologischer Studien

  • Alfred E. Buxton
  • F. E. Marchlinski
  • M. E. Rosenthal
  • B. Flores
  • J. M. Miller
  • M. E. Josephson
Conference paper

Zusammenfassung

Antiarrhythmika haben wie alle anderen Medikamente zusätzlich zu ihrer erwünschten Wirkung potentiell negative Effekte. Im Gegensatz zu den meisten anderen Therapeutika können Antiarrhythmika jedoch zusätzlich zu einer systemischen Toxizität potentiell die Bedingungen verschlechtern, die sie ursprünglich verbessern sollten. Darüber hinaus sind die durch diese Antiarrhythmika exazerbierten Arrhythmien häufig unvorhersehbar, beginnen plötzlich und können unmittelbar lebensbedrohliche Folgen haben. Der Arzt ist verpflichtet, dies bei der Einleitung oder Änderung einer pharmakologischen antiarrhythmischen Therapie zu berücksichtigen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Selzer A, Wray HW (1964) Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30: 17–26PubMedGoogle Scholar
  2. 2.
    Roden DM, Woosley RL, Primm RK (1986) Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111: 1008–1093CrossRefGoogle Scholar
  3. 3.
    Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886–894PubMedCrossRefGoogle Scholar
  4. 4.
    Flecainide Ventricular Tachycardia Study Group (1986) Treatment of resistant ventricular tachycardia with flecainide acetate. Am J Cardiol 57: 1299–1304CrossRefGoogle Scholar
  5. 5.
    Soyka LF (1986) Safety of encainide for the treatment of ventricular arrhythmias. Am J Cardiol 58: 96C–103CPubMedCrossRefGoogle Scholar
  6. 6.
    Buxton AE, Josephson ME (1986) Role of electrophysiologic studies in identifying arrhythmogenic properties of antiarrhythmic drugs. Circulation 73: II67–II72PubMedGoogle Scholar
  7. 7.
    Ruskin JN, McGovern B, Garan H, DiMarco JP, Kelly E (1983) Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med 309: 1302–1306PubMedCrossRefGoogle Scholar
  8. 8.
    Wit AL, Rosen MR (1981) Cellular electrophysiology of cardiac arrhythmias. Modern Concepts of Cardiovascular Disease 50: 1–6PubMedGoogle Scholar
  9. 9.
    Henning B, Wit AL (1982) Multiple mechanisms for antiarrhythmic drug action on delayed afterdepolarizations and triggered activity in canine coronary sinus. Am J Cardiol 49: 914 (abstr)Google Scholar
  10. 10.
    Roden DM, Thompson KA, Hoffman BF, Woosley RL (1986) Clinical features and basic mechanisms of quinidine-induced arrhythmias. JACC 8: 73A–78APubMedGoogle Scholar
  11. 11.
    Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R (1983) Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68: 846–856PubMedCrossRefGoogle Scholar
  12. 12.
    Levine JH, Spear JF, Guarnieri T, Weisfeldt ML, DeLangen CDJ, Becker LC, Moore EN (1985) Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 72: 1092–1103PubMedCrossRefGoogle Scholar
  13. 13.
    Allessie MA, Bonke FIM, Schopman FJG (1976) Circus movement in rabbit atrial muscle as a mechanism of tachycardia. Circ Research 41: 9–18Google Scholar
  14. 14.
    Wit AL, Rosen MR (1981) Cellular electrophysiology of cardiac arrhythmias. Modern Concepts of Cardiovascular Disease 50: 7–12PubMedGoogle Scholar
  15. 15.
    Horowitz LN, Greenspan AM, Spielman SR, Josephson ME (1981) Torsades de Pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities. Circulation 63: 1120–1128PubMedCrossRefGoogle Scholar
  16. 16.
    Wellens HJJ, Vermeulen A, Durrer D (1972) Ventricular fibrillation occurring on arousal from sleep by auditory stimuli. Circulation 46: 661–665PubMedGoogle Scholar
  17. 17.
    Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM (1985) Electrophysiologic testing in patients with the long QT syndrome. Circulation 71: 63–71PubMedCrossRefGoogle Scholar
  18. 18.
    Bhandari AK, Au PK, Rahimtoola SH (1986) Procainamide induced sustained monomorphic ventricular tachycardia in a patient with benign premature ventricular complexes. Can J Cardiol 2: 6–9PubMedGoogle Scholar
  19. 19.
    Grogan EW, Buxton AE, Marchlinski FE, Doherty JU, Josephson ME (1985) Incessant ventricular tachycardia: clinical characteristics, precipitating factors, and results of treatment. JACC 5 (suppl): 472Google Scholar
  20. 20.
    Winkle RA, Mason JW, Griffin JC, Ross D (1981) Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 102: 857PubMedCrossRefGoogle Scholar
  21. 21.
    Morganroth J, Horowitz LN (1984) Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53: 89 BCrossRefGoogle Scholar
  22. 22.
    Tordjman T, Podrid PJ, Raeder E, Lown B (1986) Safety and efficacy of encainide for malignant ventricular arrhythmias. Am J Cardiol 58: 87C–95CPubMedCrossRefGoogle Scholar
  23. 23.
    Horowitz LN (1986) Encainide in lethal ventricular arrhythmias evaluated by elektrophysiologic testing and decrease in symptoms. Am J Cardiol 58: 83C–86CPubMedCrossRefGoogle Scholar
  24. 24.
    Duff HJ, Roden DM, Dawson AK, Oates JA, Smith RF, Woosley RL (1982) Comparison of the effects of placebo and encainide on programmed electical stimulation and ventricular arrhythmia frequency. Am J Cardiol 50: 305PubMedCrossRefGoogle Scholar
  25. 25.
    DiBianco R, Fletcher RD, Cohen AI, Gottdiener JS, Singh SN, Katz RJ, Bates HR, Sauerbrunn B (1982) Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies. Circulation 65: 1134PubMedCrossRefGoogle Scholar
  26. 26.
    Gulamhusein S, Ko P, Carruthers SG, Klein GJ (1982) Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 65: 348–354PubMedCrossRefGoogle Scholar
  27. 27.
    McGovern B, Garan H, Ruskin JN (1986) Precipitation of cardiac arrest by verapamil in patients with Wolff- Parkinson-White syndrome. Ann Int Med 104: 791–794PubMedGoogle Scholar
  28. 28.
    Stewart RB, Bardy GH, Greene HL (1986) Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Int Medicine 104: 766–771Google Scholar
  29. 29.
    Tonkin AM, Heddle WF, Tornos P (1978) Intermittent atrioventricular block: procainamide administration as a provocative test. Aust NZ J Med 8: 594CrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1987

Authors and Affiliations

  • Alfred E. Buxton
    • 3
  • F. E. Marchlinski
    • 1
    • 2
  • M. E. Rosenthal
    • 1
    • 2
  • B. Flores
    • 1
    • 2
  • J. M. Miller
    • 1
    • 2
  • M. E. Josephson
    • 1
    • 2
  1. 1.Clinical Electrophysiology LaboratoryHospital of the University of PennsylvaniaUSA
  2. 2.Cardiovascular Section, Department of MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Clinical Electrophysiology LaboratoryHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations